This randomized phase 2 study (NEOpredict-Lung, NCT04205552) investigated the feasibility and safety of preoperative nivolumab (anti-PD-1) with or without relatlimab (anti-LAG-3) in 60 biomarker-unselected patients with resectable non-small-cell lung cancer. All patients underwent surgery within 43 days, with 95% achieving curative resection. Higher pathological and radiographic response rates were observed in the nivolumab plus relatlimab arm. At 12 months, disease-free and overall survival rates were superior in the combination arm. Both treatments showed acceptable safety profiles. Exploratory analyses provided insights into immunotherapy's biological effects.
Publisher
Nature Medicine
Published On
Jun 01, 2024
Authors
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Tags
lung cancer
nivolumab
relatlimab
immunotherapy
surgery
disease-free survival
pathological response
Related Publications
Explore these studies to deepen your understanding of the subject.
